Redcare Pharmacy N.V.

Earnings Release • Oct 3, 2024

Time to accelerate Rx due to convincing results.

● MARKET UPDATE | 4 OCTOBER 2024

Third quarter highlights.

• Group sales +21% yoy to EUR 574M in Q3, ytd +34% to EUR 1.7bn.

• Non-Rx sales +20% yoy to EUR 383M in Q3, ytd also +20% to EUR 1.2bn.

• Rx sales Germany +81% yoy to EUR 69M in Q3, accelerating in September to +108%. Ytd +42% to EUR 157M.

• Active customer base up 0.4M to 11.9M in Q3, up 1.4M yoy.

E-RX STRATEGY )

Convincing Rx results. Time to accelerate.

• ▶ Strong inflow from new customers buying e-Rx and converting existing non-Rx customers to e-Rx.

• Based on very positive metrics of these e-Rx customers, strategic move to build on the momentum.

• ▶ Decision to increase Rx marketing; being agile and data-driven in marketing is our DNA.

Marketing power to unleash the full e-Rx potential.

SOCIAL SIGNIFICANCE

Online pharmacies increasingly pivotal in the supply of medication.

Today, online pharmacies are already a cornerstone in the distribution of OTC/BPC and now increasingly so in Rx.

Accessibility. A

Enabling patients to conveniently access medications from anvwhere at anytime.

Affordability. A

Providing patients with cost effective medications.

Availability.

Offering a wide range of medications for optimal supply.

Exceptional growth, dynamic acceleration of our Rx sales in Germany.

E-Rx growth from 7% in Q1, to 37% in Q2, to 81% in Q3 and within the quarter accelerating to 108% in September.

108

E-Rx's compelling metrics. First facts.

• Fully digital customer journey, secure and convenient, high percentage NFC-rate.

• Number 1 pharmacy app in Germany, rating of 4.8 in iOS and 4.7 in Android.

• High customer satisfaction with NPS already comparable to our overall score in Germany.

• High basket value, Rx basket almost double vs. non-Rx baskets, customers like mixed baskets too.

• Never seen before customer repeat order rate. Higher and faster compared to our paper Rx and non-Rx experience.

Customer repeat order rate boosted by digital convenience.

Source: Redcare Pharmacy

8

UPDATED GUIDANCE

E-Rx marketing step up: 2024 guidance updated.

Initial guidance:

• Total sales EUR 2.3-2.5 billion. A
• Non-Rx sales growth 15-25%. A
• ➤ MediService to grow by mid-single digits.
• Adj. EBITDA margin 2% to 4%. A
• Rx too dynamic to give guidance. A

New guidance:

• Total sales EUR 2.35-2.5 billion.

• Non-Rx sales growth 20-25%. A
• ➤ MediService to grow by lower half of single digits.
• Adj. EBITDA margin 1.2% to 2.2%. A
• Rx too dynamic to give guidance. A

Redcare's underlying business performance robust and fully in line with annual plan.

I hank

Time to ask questions.